Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BA-102
- Development stage
- Preclinical
- Lead developer
- NeuroNOS
- Modality
- Small Molecules
01
Overview
BA-102 is a small-molecule inhibitor of neuronal nitric oxide synthase (nNOS) being developed by NeuroNOS, a subsidiary of Beyond Air, in collaboration with The Hebrew University of Jerusalem. The drug is designed to reduce the production of nitric oxide in the brain, thereby lowering nitrosative stress and potentially reversing phenotypes associated with autism spectrum disorder (ASD). BA-102 has received Orphan Drug Designation from the FDA for the treatment of Phelan-McDermid Syndrome (PMS), a genetic condition often associated with ASD. Preclinical development is ongoing, with a Phase 1 clinical trial anticipated to commence by the end of 2026.
- Other names
- NeuroNOS's small-molecule drugthe NeuroNOS drug
02
Targets
NOS1 (nNOS)
Beyond the preview
Go deeper on BA-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BA-102.